Skip to main content
. 2015 Oct 13;59(11):6807–6815. doi: 10.1128/AAC.01229-15

TABLE 5.

Activity of paritaprevir or ombitasvir against chimeric GT4 transient subgenomic replicons containing amino acid variants in NS3 or NS5A

HCV GT4 replicon subtype by targeta Varianta EC50 (mean ± SD) (nM)b Fold resistancec
NS3
    4a Wild typed 0.048 ± 0.0066
D168V 15 ± 1.6 313
    4d Wild type 0.015 ± 0.001
Y56H 0.12 ± 0.028 8.0
D168V 4.7 ± 0.9 313
Y56H+D168V 188 ± 50 12,533
NS5A
    4a Wild type 0.00035 ± 0.00007
L28V 0.008 ± 0.0028 23
    4d Wild type 0.00038 ± 0.00006
L28S NDe
L28V 0.118 ± 0.016 310
M31I 0.00096 ± 0.00012 2.5
M31L 0.00039 ± 0.00008 1.0
T58A 0.00053 ± 0.00002 1.4
T58P 0.00042 ± 0.00004 1.1
T58S 0.00052 ± 0.00009 1.4
L28S+M31I ND
L28V+T58S 0.289 ± 0.029 760
a

Chimeric replicons containing the NS3 or NS5A gene cloned from a GT4a or GT4d treatment-naive clinical isolate.

b

The mean ± SD EC50 values were derived from the results from at least three independent experiments.

c

Calculated as variant EC50/wild-type EC50.

d

Wild type indicates that amino acids at resistance-associated positions match those of reference sequence 4a-ED43 or 4d-QC382.

e

ND, EC50 could not be determined due to the poor replication capacity of the chimeric replicon.